| Cell line name |
BT-474 EEI |
|---|
| Synonyms |
BT474-EEI; BT474 EEI; BT-474 Exogenous Estrogen Independent |
|---|
| Accession |
CVCL_AR96 |
|---|
| Resource Identification Initiative |
To cite this cell line use: BT-474 EEI (RRID:CVCL_AR96) |
|---|
| Comments |
Population: Caucasian.
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:24618; AHCTF1 + HGNC; HGNC:736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; HGNC:7609; MYO9B + HGNC; HGNC:9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Gene fusion; HGNC; HGNC:16173; DOK5 + HGNC; HGNC:17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; HGNC:16651; MRPL45 + HGNC; HGNC:16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; HGNC:13178; IKZF3 + HGNC; HGNC:12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0179 (BT-474) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
60Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=19010901; DOI=10.1158/0008-5472.CAN-08-1776
Lewis Phillips G.D., Li G.-M., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blattler W.A., Lambert J.M., Chari R.V.J., Lutz R.J., Wong W.L.T., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R., Spencer S.D., Sliwkowski M.X.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Cancer Res. 68:9280-9290(2008) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_AR96
|
|---|
| Encyclopedic resources |
Wikidata; Q54798463
|
|---|
| Entry history |
|---|
| Entry creation | 02-May-2016 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 13 |
|---|
